Physician profile
Edward Balzer
NPI 1720763196
$5,472.93
in general payments reported to CMS, 2019-2025
25 companies · $2,224 in 2025
The $2,224 reported for 2025 was more than what 94% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,093 · 2024: $2,155 · 2025: $2,224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,472.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $814.98 | 2023-2025 | |
| Lundbeck LLC | $643.71 | 2023-2025 | Rexulti, Abilify Asimtufii |
| Corium, LLC | $598.92 | 2023-2025 | Azstarys |
| Alkermes, INC. | $589.50 | 2023-2025 | Aristada, Lybalvi, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $500.21 | 2023-2025 | Uzedy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $469.08 | 2023-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Axsome Therapeutics, INC. | $340.07 | 2024-2025 | Auvelity, Sunosi |
| E.R. Squibb & Sons, L.L.C. | $241.65 | 2024-2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $236.40 | 2023-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $114.83 | 2023-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Idorsia Pharmaceuticals US INC | $108.96 | 2023 | Quviviq |
| Indivior INC. | $108.17 | 2024-2025 | Sublocade, Perseris |
| Tris Pharma INC | $104.36 | 2023-2025 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $103.46 | 2023-2025 | Trintellix |
| Collegium Pharmaceutical, INC. | $92.83 | 2025 | Jornay Pm |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $73.02 | 2024-2025 | Ingrezza |
| Avion Pharmaceuticals | $59.64 | 2023-2024 | Methylphenidate Hydrochloride, Relexxii |
| Biogen, INC. | $56.21 | 2024-2025 | Zurzuvae |
| Vertical Pharmaceuticals, LLC | $50.26 | 2023-2025 | Relexxii |
| Vanda Pharmaceuticals INC. | $46.12 | 2025 | Fanapt |
| Almatica Pharma LLC | $35.04 | 2024-2025 | Loreev Xr |
| Supernus Pharmaceuticals, INC. | $28.94 | 2024 | Qelbree |
| Harmony Biosciences LLC | $24.23 | 2024 | |
| Bausch Health US, LLC | $18.05 | 2024 | Aplenzin |
| Neos Therapeutics, LP | $14.29 | 2024 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Balzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.